Drug Profile
Autologous stem cell therapy - CellPraxis/Cryopraxis
Alternative Names: MonoCell; ReACT; Refractory angina cell therapyLatest Information Update: 29 Oct 2021
Price :
$50
*
At a glance
- Originator CellPraxis; Cryopraxis
- Class Mesenchymal stem cell therapies
- Mechanism of Action Angiogenesis inducing agents; Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Angina pectoris
Most Recent Events
- 13 Aug 2015 No recent reports on development identified - Phase-II for Angina pectoris (Treatment-experienced) in Brazil (Intracardiac)
- 06 Nov 2012 Cryopraxis and CellPraxis plan a Phase-III trial for Angina pectoris (treatment-experienced patients) in Brazil
- 31 Dec 2011 Cryopraxis and CellPraxis complete a Phase-II trial in Angina pectoris (treatment-experienced patients) in Brazil